FCGRT and autoimmune disease: The proof-of-principle that decreasing IgG levels by targeting FcRn could be therapeutically relevant for treating autoimmune diseases comes from disease models, such as rat EAMG and mouse experimental arthritis, where AbDegs reduce total IgG levels by approximately 60% (Liu et al., 2007a; Patel et al., 2011).